{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:31:34Z","timestamp":1790353894269,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40265-024-02094-5","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T23:35:20Z","timestamp":1727307320000},"page":"1179-1197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management"],"prefix":"10.1007","volume":"84","author":[{"given":"Konstantina","family":"Kitsou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kokkotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Rivera\u2011Nieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-5717","authenticated-orcid":false,"given":"Giorgos","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"2094_CR1","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ueg2.12317","volume":"10","author":"M Agrawal","year":"2022","unstructured":"Agrawal M, Jess T. Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United Eur Gastroenterol J. 2022;10:1113.","journal-title":"United Eur Gastroenterol J."},{"key":"2094_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12874-023-01944-2","volume":"23","author":"JWY Mak","year":"2023","unstructured":"Mak JWY, Sun Y, Limsrivilai J, Abdullah M, Kaibullayeva J, Balderramo D, et al. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). BMC Med Res Methodol. 2023;23:129.","journal-title":"BMC Med Res Methodol"},{"key":"2094_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","volume":"10","author":"AD Levin","year":"2016","unstructured":"Levin AD, Wildenberg ME, Van Den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016;10:989\u201397.","journal-title":"J Crohns Colitis"},{"key":"2094_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-Tnfs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7: e135.","journal-title":"Clin Transl Gastroenterol"},{"key":"2094_CR5","doi-asserted-by":"publisher","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","volume":"10","author":"C Herrera-Deguise","year":"2023","unstructured":"Herrera-Deguise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases. Front Med. 2023;10:1089099.","journal-title":"Front Med"},{"key":"2094_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ibd\/izy269","volume":"25","author":"T P\u00e9rez-Jeldres","year":"2019","unstructured":"P\u00e9rez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, et al. Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on basic pathogenesis concepts. Inflamm Bowel Dis. 2019;25:270.","journal-title":"Inflamm Bowel Dis"},{"key":"2094_CR7","doi-asserted-by":"publisher","first-page":"8813558","DOI":"10.1155\/2020\/8813558","volume":"2020","author":"JB Yan","year":"2020","unstructured":"Yan JB, Luo MM, Chen ZY, He BH. The function and role of the Th17\/Treg cell balance in inflammatory bowel disease. J Immunol Res. 2020;2020:8813558.","journal-title":"J Immunol Res"},{"key":"2094_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/eji.201545805","volume":"46","author":"F Ottenlinger","year":"2016","unstructured":"Ottenlinger F, Schwiebs A, Pfarr K, Wagner A, Gr\u00fcner S, Mayer CA, et al. Fingolimod Targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-\u0393 production in CD8(+) lymphocytes. Eur J Immunol. 2016;46:941\u201351.","journal-title":"Eur J Immunol"},{"key":"2094_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1021\/ml300396r","volume":"4","author":"S Pan","year":"2013","unstructured":"Pan S, Gray NS, Gao W, Mi Y, Fan Y, Wang X, et al. Discovery of BAF312 (Siponimod), a potent and selective S1P receptor modulator. ACS Med Chem Lett. 2013;4:333\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"2094_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/jcph.887","volume":"57","author":"JQ Tran","year":"2017","unstructured":"Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J Clin Pharmacol. 2017;57:988\u201396.","journal-title":"J Clin Pharmacol"},{"key":"2094_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","volume":"22","author":"M Maceyka","year":"2012","unstructured":"Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50.","journal-title":"Trends Cell Biol"},{"key":"2094_CR12","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1111\/bph.14451","volume":"175","author":"F Tukijan","year":"2018","unstructured":"Tukijan F, Chandrakanthan M, Nguyen LN. The signalling roles of sphingosine-1-phosphate derived from red blood cells and platelets. Br J Pharmacol. 2018;175:3741.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"2094_CR13","doi-asserted-by":"publisher","first-page":"H1011","DOI":"10.1152\/ajpheart.00829.2013","volume":"306","author":"RH Adamson","year":"2014","unstructured":"Adamson RH, Clark JF, Radeva M, Kheirolomoom A, Ferrara KW, Curry FE. Albumin modulates S1P delivery from red blood cells in perfused microvessels: mechanism of the protein effect. Am J Physiol Heart Circ Physiol. 2014;306(7):H1011\u20137.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2094_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-15043-y","volume":"7","author":"PM Christensen","year":"2017","unstructured":"Christensen PM, Bosteen MH, Hajny S, Nielsen LB, Christoffersen C. Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes. Sci Rep. 2017;7:1\u201310.","journal-title":"Sci Rep"},{"key":"2094_CR15","doi-asserted-by":"publisher","first-page":"7685142","DOI":"10.1155\/2017\/7685142","volume":"2017","author":"A Kumar","year":"2017","unstructured":"Kumar A, Zamora-Pineda J, Degagn\u00e9 E, Saba JD. S1P lyase regulation of thymic egress and oncogenic inflammatory signaling. Mediat Inflamm. 2017;2017:7685142.","journal-title":"Mediat Inflamm"},{"key":"2094_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/imm.12272","volume":"142","author":"CS Garris","year":"2014","unstructured":"Garris CS, Blaho VA, Hla T, Han MH. Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond. Immunology. 2014;142:347.","journal-title":"Immunology"},{"key":"2094_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/ni.1939","volume":"11","author":"G Liu","year":"2010","unstructured":"Liu G, Yang K, Burns S, Shrestha S, Chi H. S1P1-Mtor axis directs the reciprocal differentiation of TH1 and regulatory T cells. Nat Immunol. 2010;11:1047.","journal-title":"Nat Immunol"},{"key":"2094_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-13376-2","volume":"7","author":"A Eken","year":"2017","unstructured":"Eken A, Duhen R, Singh AK, Fry M, Buckner JH, Kita M, et al. S1P1 deletion differentially affects TH17 and regulatory T cells. Sci Rep. 2017;7:1\u201313.","journal-title":"Sci Rep"},{"key":"2094_CR19","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/s41375-019-0511-z","volume":"33","author":"K Vrzalikova","year":"2019","unstructured":"Vrzalikova K, Ibrahim M, Vockerodt M, Perry T, Margielewska S, Lupino L, et al. Correction: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of hodgkin lymphoma cells. Leukemia. 2019;33:2126.","journal-title":"Leukemia"},{"key":"2094_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1084\/jem.20092210","volume":"207","author":"ML Allende","year":"2010","unstructured":"Allende ML, Tuymetova G, Lee BG, Bonifacino E, Wu YP, Proia RL. S1P1 receptor directs the release of immature B cells from bone marrow into blood. J Exp Med. 2010;207:1113.","journal-title":"J Exp Med"},{"key":"2094_CR21","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.88204","volume":"12","author":"H Chen","year":"2023","unstructured":"Chen H, Qin Y, Chou M, Cyster JG, Li X. Transmembrane protein CD69 acts as an S1PR1 agonist. Elife. 2023;12: e88204.","journal-title":"Elife"},{"key":"2094_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.21037\/atm-21-6679","volume":"10","author":"B Wang","year":"2022","unstructured":"Wang B, Dong N, Wu D, Fang Y, Chen J, Lin Y, et al. Sphingosine 1-phosphate receptor 1 governs endothelial barrier function and angiogenesis by upregulating endoglin signaling. Ann Transl Med. 2022;10:136.","journal-title":"Ann Transl Med."},{"key":"2094_CR23","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1073\/pnas.1906246117","volume":"117","author":"A Cartier","year":"2020","unstructured":"Cartier A, Leigh T, Liu CH, Hla T. Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy. Proc Natl Acad Sci. 2020;117:3157\u201366.","journal-title":"Proc Natl Acad Sci"},{"key":"2094_CR24","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/biom13050818","volume":"13","author":"N Wang","year":"2023","unstructured":"Wang N, Li J-Y, Zeng B, Chen G-L. Sphingosine-1-phosphate signaling in cardiovascular diseases. Biomolecules. 2023;13:818.","journal-title":"Biomolecules"},{"key":"2094_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104775","volume":"299","author":"C Weigel","year":"2023","unstructured":"Weigel C, Bellaci J, Spiegel S. Sphingosine-1-phosphate and its receptors in vascular endothelial and lymphatic barrier function. J Biol Chem. 2023;299: 104775.","journal-title":"J Biol Chem"},{"key":"2094_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/cvr\/cvp064","volume":"82","author":"J Igarashi","year":"2009","unstructured":"Igarashi J, Michel T. Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc Res. 2009;82:212\u201320.","journal-title":"Cardiovasc Res"},{"key":"2094_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003393","volume":"5","author":"P Keul","year":"2016","unstructured":"Keul P, Van Borren MMGJ, Ghanem A, M\u00fcller FU, Baartscheer A, Verkerk AO, et al. Sphingosine-1-phosphate receptor 1 regulates cardiac function by modulating Ca2+ sensitivity and Na+\/H+ exchange and mediates protection by ischemic preconditioning. J Am Heart Assoc. 2016;5: e003393.","journal-title":"J Am Heart Assoc"},{"key":"2094_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1369\/jhc.2010.956409","volume":"58","author":"H Nishimura","year":"2010","unstructured":"Nishimura H, Akiyama T, Irei I, Hamazaki S, Sadahira Y. Cellular localization of sphingosine-1-phosphate receptor 1 expression in the human central nervous system. J Histochem Cytochem. 2010;58:847\u201356.","journal-title":"J Histochem Cytochem"},{"key":"2094_CR29","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","volume":"81","author":"T P\u00e9rez-Jeldres","year":"2021","unstructured":"P\u00e9rez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. Drugs. 2021;81:985\u20131002.","journal-title":"Drugs"},{"key":"2094_CR30","doi-asserted-by":"publisher","first-page":"13703","DOI":"10.1080\/21655979.2022.2076500","volume":"13","author":"T Chen","year":"2022","unstructured":"Chen T, Gu K, Lin R, Liu Y, Shan Y. The function of sphingosine-1-phosphate receptor 2 (S1PR2) in maintaining intestinal barrier and inducing ulcerative colitis. Bioengineered. 2022;13:13703\u201317.","journal-title":"Bioengineered"},{"key":"2094_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/ni.2047","volume":"12","author":"JA Green","year":"2011","unstructured":"Green JA, Suzuki K, Cho B, Willison LD, Palmer D, Allen CDC, et al. The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol. 2011;12:672\u201380.","journal-title":"Nat Immunol"},{"key":"2094_CR32","doi-asserted-by":"publisher","first-page":"L609","DOI":"10.1152\/ajplung.00554.2017","volume":"315","author":"L Liu","year":"2018","unstructured":"Liu L, Zhai C, Pan Y, Zhu Y, Shi W, Wang J, et al. Sphingosine-1-phosphate induces airway smooth muscle cell proliferation, migration, and contraction by modulating hippo signaling effector YAP. Am J Physiol Lung Cell Mol Physiol. 2018;315:L609\u201321.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2094_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9081770","volume":"9","author":"D Wafa","year":"2020","unstructured":"Wafa D, Koch N, Kov\u00e1cs J, Ker\u00e9k M, Proia RL, Tigyi GJ, et al. Opposing roles of S1P3 receptors in myocardial function. Cells. 2020;9:1\u201317.","journal-title":"Cells"},{"key":"2094_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104793","volume":"156","author":"E Jozefczuk","year":"2020","unstructured":"Jozefczuk E, Guzik TJ, Siedlinski M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol Res. 2020;156: 104793.","journal-title":"Pharmacol Res"},{"key":"2094_CR35","doi-asserted-by":"publisher","first-page":"6059203","DOI":"10.1155\/2017\/6059203","volume":"2017","author":"C Olesch","year":"2017","unstructured":"Olesch C, Ringel C, Br\u00fcne B, Weigert A. Beyond immune cell migration: the emerging role of the sphingosine-1-phosphate receptor S1PR4 as a modulator of innate immune cell activation. Mediat Inflamm. 2017;2017:6059203.","journal-title":"Mediat Inflamm"},{"key":"2094_CR36","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1096\/fj.10-179028","volume":"25","author":"T Schulze","year":"2011","unstructured":"Schulze T, Golfier S, Tabeling C, R\u00e4bel K, Gr\u00e4ler MH, Witzenrath M, et al. Sphingosine-1-phospate receptor 4 (S1P4) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model. FASEB J. 2011;25:4024\u201336.","journal-title":"FASEB J"},{"key":"2094_CR37","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1172\/JCI136928","volume":"130","author":"C Olesch","year":"2020","unstructured":"Olesch C, Sirait-Fischer E, Berkefeld M, Fink AF, Susen RM, Ritter B, et al. S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion. J Clin Investig. 2020;130:5461\u201376.","journal-title":"J Clin Investig"},{"key":"2094_CR38","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.4049\/jimmunol.1403168","volume":"196","author":"C Dillmann","year":"2016","unstructured":"Dillmann C, Ringel C, Ringleb J, Mora J, Olesch C, Fink AF, et al. S1PR4 signaling attenuates ILT 7 internalization to limit IFN-\u03b1 production by human plasmacytoid dendritic cells. J Immunol. 2016;196:1579\u201390.","journal-title":"J Immunol"},{"key":"2094_CR39","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1007\/s10620-010-1421-0","volume":"56","author":"J Greenspon","year":"2011","unstructured":"Greenspon J, Li R, Xiao L, Rao JN, Sun R, Strauch ED, et al. Sphingosine-1-phosphate regulates the expression of adherens junction protein E-cadherin and enhances intestinal epithelial cell barrier function. Dig Dis Sci. 2011;56:1342\u201353.","journal-title":"Dig Dis Sci"},{"key":"2094_CR40","doi-asserted-by":"publisher","first-page":"9660","DOI":"10.1074\/jbc.M114.609685","volume":"290","author":"ES Park","year":"2015","unstructured":"Park ES, Choi S, Shin B, Yu J, Yu J, Hwang JM, et al. Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-sphingosine 1-phosphate (S1P) interaction. J Biol Chem. 2015;290:9660\u201373.","journal-title":"J Biol Chem"},{"key":"2094_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ni.2810","volume":"15","author":"KB Harikumar","year":"2014","unstructured":"Harikumar KB, Yester JW, Surace MJ, Oyeniran C, Price MM, Huang WC, et al. K63-linked polyubiquitylation of IRF1 transcription factor is essential for IL-1-induced CCL5 and CXCL10 chemokine production. Nat Immunol. 2014;15:231.","journal-title":"Nat Immunol"},{"key":"2094_CR42","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.1176709","volume":"325","author":"NC Hait","year":"2009","unstructured":"Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325:1254\u20137.","journal-title":"Science"},{"key":"2094_CR43","first-page":"4478","volume":"13","author":"M Zhang","year":"2023","unstructured":"Zhang M, Hei R, Zhou Z, Xiao W, Liu X, Chen Y. Macrophage polarization involved the inflammation of chronic obstructive pulmonary disease by S1P\/HDAC1 signaling. Am J Cancer Res. 2023;13:4478.","journal-title":"Am J Cancer Res"},{"key":"2094_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ccr.2012.11.013","volume":"23","author":"J Liang","year":"2013","unstructured":"Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23:107\u201320.","journal-title":"Cancer Cell"},{"key":"2094_CR45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/mi.2016.35","volume":"10","author":"T Karuppuchamy","year":"2017","unstructured":"Karuppuchamy T, Behrens EH, Gonz\u00e1lez-Cabrera P, Sarkisyan G, Gima L, Boyer JD, et al. Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol. 2017;10:162.","journal-title":"Mucosal Immunol"},{"key":"2094_CR46","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1194\/jlr.M034108","volume":"54","author":"DC Montrose","year":"2013","unstructured":"Montrose DC, Scherl EJ, Bosworth BP, Zhou XK, Jung B, Dannenberg AJ, et al. S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J Lipid Res. 2013;54:843.","journal-title":"J Lipid Res"},{"key":"2094_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1136\/gutjnl-2023-330009","volume":"73","author":"Y Ma","year":"2024","unstructured":"Ma Y, Zhang X, Xuan B, Li D, Yin N, Ning L, et al. Disruption of Cers6-mediated sphingolipid metabolism by FTO deficiency aggravates ulcerative colitis. Gut. 2024;73:268\u201381.","journal-title":"Gut"},{"key":"2094_CR48","doi-asserted-by":"publisher","first-page":"11078","DOI":"10.1002\/jcp.27944","volume":"234","author":"A Yousefi-Ahmadipour","year":"2019","unstructured":"Yousefi-Ahmadipour A, Rashidian A, Mirzaei MR, Farsinejad A, Pourmohammadi-Nejad F, Ghazi-Khansari M, et al. Combination therapy of mesenchymal stromal cells and sulfasalazine attenuates trinitrobenzene sulfonic acid induced colitis in the rat: the S1P pathway. J Cell Physiol. 2019;234:11078\u201391.","journal-title":"J Cell Physiol"},{"key":"2094_CR49","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ibd\/izy007","volume":"24","author":"JH Suh","year":"2018","unstructured":"Suh JH, Degagn\u00e9 \u00c9, Gleghorn EE, Setty M, Rodriguez A, Park KT, et al. Sphingosine-1-phosphate signaling and metabolism gene signature in pediatric inflammatory bowel disease: a matched-case control pilot study. Inflamm Bowel Dis. 2018;24:1321.","journal-title":"Inflamm Bowel Dis"},{"key":"2094_CR50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.bbrc.2017.03.043","volume":"494","author":"T Chen","year":"2017","unstructured":"Chen T, Xue H, Lin R, Huang Z. Mir-126 impairs the intestinal barrier function via inhibiting S1PR2 mediated activation of PI3K\/AKT signaling pathway. Biochem Biophys Res Commun. 2017;494:427\u201332.","journal-title":"Biochem Biophys Res Commun"},{"key":"2094_CR51","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1111\/jgh.15067","volume":"35","author":"S Iwatani","year":"2020","unstructured":"Iwatani S, Iijima H, Otake Y, Amano T, Tani M, Yoshihara T, et al. Novel mass spectrometry-based comprehensive lipidomic analysis of plasma from patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2020;35:1355\u201364.","journal-title":"J Gastroenterol Hepatol"},{"key":"2094_CR52","first-page":"265","volume":"18","author":"T Choden","year":"2022","unstructured":"Choden T, Cohen NA, Rubin DT. Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease. Gastroenterol Hepatol NY. 2022;18:265.","journal-title":"Gastroenterol Hepatol NY."},{"key":"2094_CR53","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s40265-017-0814-1","volume":"77","author":"G Comi","year":"2017","unstructured":"Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H. Benefit\u2013risk profile of sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis. Drugs. 2017;77:1755\u201368.","journal-title":"Drugs"},{"key":"2094_CR54","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"WJ Sandborn","year":"2016","unstructured":"Sandborn WJ, Feagan BG, Wolf DC, D\u2019Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374:1754\u201362.","journal-title":"N Engl J Med"},{"key":"2094_CR55","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G, Wolf DC, Jovanovic I, Hanauer SB, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385:1280\u201391.","journal-title":"N Engl J Med"},{"key":"2094_CR56","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","volume":"15","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, et al. Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE study. J Crohns Colitis. 2021;15:1120\u20139.","journal-title":"J Crohns Colitis"},{"key":"2094_CR57","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","volume":"18","author":"S Danese","year":"2024","unstructured":"Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the true north open-label extension. J Crohns Colitis. 2024;18:264\u201374.","journal-title":"J Crohns Colitis"},{"key":"2094_CR58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10620-023-08178-8","volume":"69","author":"NA Cohen","year":"2024","unstructured":"Cohen NA, Choi D, Garcia N, Choi NK, Picker E, Krugliak Cleveland N, et al. Real world clinical effectiveness and safety of ozanimod in the treatment of ulcerative colitis: 1-year follow-up from a tertiary center. Dig Dis Sci. 2024;69:579\u201387.","journal-title":"Dig Dis Sci"},{"key":"2094_CR59","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","volume":"5","author":"BG Feagan","year":"2020","unstructured":"Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, et al. Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5:819\u201328.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2094_CR60","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/ecco-jcc\/jjad112","volume":"17","author":"BE Sands","year":"2023","unstructured":"Sands BE, Schreiber S, Blumenstein I, Chiorean MV, Ungaro RC, Rubin DT. Clinician\u2019s guide to using ozanimod for the treatment of ulcerative colitis. J Crohns Colitis. 2023;17:2012\u201325.","journal-title":"J Crohns Colitis"},{"key":"2094_CR61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/cpdd.383","volume":"7","author":"JQ Tran","year":"2018","unstructured":"Tran JQ, Hartung JP, Olson AD, Mendzelevski B, Timony GA, Boehm MF, et al. Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT\/Qtc study. Clin Pharmacol Drug Dev. 2018;7:263\u201376.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"2094_CR62","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpdd.409","volume":"7","author":"JQ Tran","year":"2018","unstructured":"Tran JQ, Hartung JP, Tompkins C-A, Frohna PA. Effects of high- and low-fat meals on the pharmacokinetics of ozanimod, a novel sphingosine-1-phosphate receptor modulator. Clin Pharmacol Drug Dev. 2018;7:634\u201340.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"2094_CR63","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1053\/j.gastro.2021.12.036","volume":"162","author":"J Shen","year":"2022","unstructured":"Shen J, Tatosian D, Sid-Otmane L, Teuscher N, Chen L, Zhang P, et al. Population pharmacokinetics of ozanimod and active metabolite CC112273 in patients with ulcerative colitis. Gastroenterology. 2022;162:S17\u20138.","journal-title":"Gastroenterology"},{"key":"2094_CR64","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158:550\u201361.","journal-title":"Gastroenterology"},{"key":"2094_CR65","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjae007","volume":"18","author":"AJ Yarur","year":"2024","unstructured":"Yarur AJ, Chiorean MV, Pan\u00e9s J, Jairath V, Zhang J, Rabbat CJ, et al. Achievement of clinical, endoscopic, and histological outcomes in patients with ulcerative colitis treated with etrasimod, and association with faecal calprotectin and C-reactive protein: results from the phase 2 OASIS trial. J Crohns Colitis. 2024;18:885\u201394.","journal-title":"J Crohns Colitis"},{"key":"2094_CR66","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159\u201371.","journal-title":"Lancet"},{"key":"2094_CR67","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Chiorean M, Pan\u00e9s J, Peyrin-Biroulet L, Zhang J, Sands BE, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohns Colitis. 2021;15:950\u20139.","journal-title":"J Crohns Colitis"},{"issue":"8","key":"2094_CR68","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/ecco-jcc\/jjae098","volume":"18","author":"C To","year":"2024","unstructured":"To C. Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: results from the phase 3 ELEVATE UC clinical programme. J Crohns Colitis. 2024;18(8):1356.","journal-title":"J Crohns Colitis"},{"key":"2094_CR69","doi-asserted-by":"publisher","first-page":"I764","DOI":"10.1093\/ecco-jcc\/jjac190.0762","volume":"17","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky MC, Peyrin-Biroulet L, Danese S, Sands BE, Wolf DC, et al. P632 etrasimod induction therapy in moderately to severely active Crohn\u2019s disease: results from a phase 2, randomised, double-blind substudy. J Crohns Colitis. 2023;17:I764\u20135.","journal-title":"J Crohns Colitis"},{"key":"2094_CR70","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cpdd.1379","volume":"13","author":"CA Lee","year":"2024","unstructured":"Lee CA, Schreiber S, Bressler B, Adams JW, Oh DA, Tang YQ, et al. Safety, pharmacokinetics, and pharmacodynamics of etrasimod: single and multiple ascending dose studies in healthy adults. Clin Pharmacol Drug Dev. 2024;13:534\u201348.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"2094_CR71","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.3390\/jcm12155014","volume":"12","author":"S Bencardino","year":"2023","unstructured":"Bencardino S, D\u2019Amico F, Faggiani I, Bernardi F, Allocca M, Furfaro F, et al. Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis. J Clin Med. 2023;12:5014.","journal-title":"J Clin Med"},{"key":"2094_CR72","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.14309\/01.ajg.0000995744.18012.0c","volume":"118","author":"J Qian","year":"2023","unstructured":"Qian J, Tian Z, Li Y, Xu F, Wang F, Zhang X, et al. S2 Efficacy and safety of icanbelimod (CBP-307) in adults with moderate to severe ulcerative colitis: a phase 2, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2023;118:S1\u2013S1.","journal-title":"Am J Gastroenterol"},{"key":"2094_CR73","doi-asserted-by":"publisher","first-page":"1380975","DOI":"10.3389\/fimmu.2024.1380975","volume":"15","author":"J Lickliter","year":"2024","unstructured":"Lickliter J, Yang X, Guo J, Pan W, Wei Z. Icanbelimod (CBP-307), a next-generation sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia. Front Immunol. 2024;15:1380975.","journal-title":"Front Immunol"},{"key":"2094_CR74","doi-asserted-by":"publisher","first-page":"I4","DOI":"10.1093\/ecco-jcc\/jjad212.0003","volume":"18","author":"BE Sands","year":"2024","unstructured":"Sands BE, Panaccione R, D\u2019Haens G, Schreiber S, Duvall A, Kierkus J, et al. OP03 efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active ulcerative colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial. J Crohns Colitis. 2024;18:I4-5.","journal-title":"J Crohns Colitis"},{"key":"2094_CR75","doi-asserted-by":"publisher","first-page":"I878","DOI":"10.1093\/ecco-jcc\/jjac190.0878","volume":"17","author":"R Gregg","year":"2023","unstructured":"Gregg R, Yun C, Naik S, Huyghe M, Harris J, Mohan R, et al. P748 pharmacokinetics, relative bioavailability, and dose proportionality of a tablet formulation of the sphingosine 1-phosphate-1 receptor modulator VTX002 (formerly OPL-002). J Crohns Colitis. 2023;17:I878\u20139.","journal-title":"J Crohns Colitis"},{"key":"2094_CR76","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/ibd\/izaa347.001","volume":"27","author":"S Hanauer","year":"2021","unstructured":"Hanauer S, O\u2019Reilly T, Lester R, Slatkin N, Lee J, Franklin H, et al. Safety of amiselimod in healthy subjects: results from a phase 1 randomized, double-blind, placebo-controlled study. Inflamm Bowel Dis. 2021;27:S1\u2013S1.","journal-title":"Inflamm Bowel Dis"},{"key":"2094_CR77","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/ecco-jcc\/jjab201","volume":"16","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Danese S, Davies M, Watanabe M, Hibi T. A phase II, multicentre, randomised, double-blind, placebo-controlled study to evaluate safety, tolerability, and efficacy of amiselimod in patients with moderate to severe active Crohn\u2019s disease. J Crohns Colitis. 2022;16:746\u201356.","journal-title":"J Crohns Colitis"},{"key":"2094_CR78","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1053\/j.gastro.2019.11.044","volume":"158","author":"GRAM D\u2019Haens","year":"2020","unstructured":"D\u2019Haens GRAM, Slatkin N, Israel R, Heimanson Z. P097 favorable safety profile for amiselimod, a selective S1p receptor modulator, in Crohn\u2019s disease. Gastroenterology. 2020;158:S2.","journal-title":"Gastroenterology"},{"key":"2094_CR79","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/cpdd.1210","volume":"12","author":"J Lee","year":"2023","unstructured":"Lee J, Lester R, O\u2019Reilly T, Lowe ER, Slatkin NE, Franklin H, et al. A randomized, double-blind, parallel design thorough QT study with a nested crossover to compare the cardiac safety of amiselimod with placebo and positive control in healthy volunteers. Clin Pharmacol Drug Dev. 2023;12:236\u201348.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"2094_CR80","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.14309\/01.ajg.0000798716.85306.ca","volume":"116","author":"J Lee","year":"2021","unstructured":"Lee J, Lester R, O\u2019Reilly T, Lowe E, Slatkin N, Franklin H, et al. P029 pharmacokinetic\/pharmacodynamic analysis of amiselimod, a selective sphingosine 1-phosphate receptor modulator, in healthy subjects: results from a phase 1 study. Am J Gastroenterol. 2021;116:S7.","journal-title":"Am J Gastroenterol"},{"key":"2094_CR81","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/00498254.2018.1525508","volume":"49","author":"T Kifuji","year":"2019","unstructured":"Kifuji T, Inoue S, Furukawa M, Perez Madera B, Goto T, Kumagai H, et al. Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study. Xenobiotica. 2019;49:1033\u201343.","journal-title":"Xenobiotica"},{"key":"2094_CR82","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1124\/jpet.106.119172","volume":"324","author":"J Song","year":"2008","unstructured":"Song J, Matsuda C, Kai Y, Nishida T, Nakajima K, Mizushima T, et al. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J Pharmacol Exp Ther. 2008;324:276\u201383.","journal-title":"J Pharmacol Exp Ther"},{"key":"2094_CR83","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000509393","volume":"5","author":"HH Radeke","year":"2020","unstructured":"Radeke HH, Stein J, Van Assche G, Rogler G, Lakatos PL, Muellershausen F, et al. A multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the S1P receptor agonist KRP203 in patients with moderately active refractory ulcerative colitis. Inflamm Intest Dis. 2020;5:180.","journal-title":"Inflamm Intest Dis."},{"key":"2094_CR84","doi-asserted-by":"publisher","first-page":"41.e1","DOI":"10.1016\/j.jtct.2022.10.029","volume":"29","author":"S Dertschnig","year":"2023","unstructured":"Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, et al. Mocravimod, a selective sphingosine-1-phosphate receptor modulator, in allogeneic hematopoietic stem cell transplantation for malignancy. Transplant Cell Ther. 2023;29:41.e1-41.e9.","journal-title":"Transplant Cell Ther."},{"key":"2094_CR85","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/apt.17311","volume":"57","author":"D Alaskar","year":"2023","unstructured":"Alaskar D, Almusa Z, Alameel T. Letter: ozanimod and latent tuberculosis. Aliment Pharmacol Ther. 2023;57:353\u20134.","journal-title":"Aliment Pharmacol Ther"},{"key":"2094_CR86","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.prostaglandins.2017.03.006","volume":"130","author":"MJ Pulkoski-Gross","year":"2017","unstructured":"Pulkoski-Gross MJ, Uys JD, Orr-Gandy KA, Coant N, Bialkowska AB, Szulc ZM, et al. Novel sphingosine kinase-1 inhibitor, LCL351, reduces immune responses in murine DSS-induced colitis. Prostaglandins Other Lipid Mediat. 2017;130:47\u201356.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2094_CR87","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/ibd\/izz174","volume":"26","author":"T Karuppuchamy","year":"2020","unstructured":"Karuppuchamy T, Tyler CJ, Lundborg LR, P\u00e9rez-Jeldres T, Kimball AK, Clambey ET, et al. Sphingosine-1-phosphate lyase inhibition alters the S1P gradient and ameliorates Crohn\u2019s-like ileitis by suppressing thymocyte maturation. Inflamm Bowel Dis. 2020;26:216\u201328.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02094-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T11:07:18Z","timestamp":1729940838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02094-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2094"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02094-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"3 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GB has acted as advisor\/lecturer for Janssen, Pfizer, Takeda, Abbvie, MSD, Mylan, Genesis Pharma, Adacyte Therapeutics, Amgen, Ferring, Cooper; Funding (Grants\/Honoraria): Pfizer, Takeda, Abbvie, Aenorasis; Research\/Clinical Trials: Abbvie, Takeda. Genesis Pharma, Cooper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was received for the production of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KK: writing\u2014original draft, writing\u2014review and editing, GK: writing\u2014original draft, writing\u2014review and editing, JR-N: conceptualization, writing\u2014review and editing, supervision, GB: conceptualization, writing\u2014review and editing, supervision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}